In last trading session, ProKidney Corp (NASDAQ:PROK) saw 1.18 million shares changing hands with its beta currently measuring 1.52. Company’s recent per share price level of $0.99 trading at $0.08 or 8.80% at ring of the bell on the day assigns it a market valuation of $289.82M. That closing price of PROK’s stock is at a discount of -348.48% from its 52-week high price of $4.44 and is indicating a premium of 53.54% from its 52-week low price of $0.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.61 million shares which gives us an average trading volume of 722.33K if we extend that period to 3-months.
For ProKidney Corp (PROK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
ProKidney Corp (NASDAQ:PROK) trade information
Upright in the green during last session for gaining 8.80%, in the last five days PROK remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $0.99 price level, adding 1.0% to its value on the day. ProKidney Corp’s shares saw a change of -41.41% in year-to-date performance and have moved 24.41% in past 5-day. ProKidney Corp (NASDAQ:PROK) showed a performance of -1.96% in past 30-days. Number of shares sold short was 11.93 million shares which calculate 21.42 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 80.2% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -203.03% in reaching the projected high whereas dropping to the targeted low would mean a loss of -203.03% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 3.70% while estimates for its earnings growth in next 5 years are of -3.33%.
ProKidney Corp (NASDAQ:PROK)’s Major holders
Insiders are in possession of 29.75% of company’s total shares while institution are holding 44.35 percent of that, with stock having share float percentage of 63.14%. Investors also watch the number of corporate investors in a company very closely, which is 44.35% institutions for ProKidney Corp that are currently holding shares of the company. SUVRETTA CAPITAL MANAGEMENT, LLC is the top institutional holder at PROK for having 9.34 million shares of worth $22.98 million. And as of 2024-06-30, it was holding 12.306 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 3.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.237 of outstanding shares, having a total worth of $9.78 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and MORGAN STANLEY INSTITUTIONAL FUND INC-GROWTH PORTFOLIO are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.97 shares of worth $2.94 million or 2.29% of the total outstanding shares. The later fund manager was in possession of 2.92 shares on Dec 31, 2024 , making its stake of worth around $2.9 million in the company or a holder of 2.26% of company’s stock.
